Cybin Logo

(NEO: CYBN) Cybin Gives Update on Key Patents

Share on facebook
Share on twitter
Share on linkedin
Share on email

Developments Come at Critical Moment for Industry-Defining Psychedelic Research/Treatments

Beginning 2021 with good news for its investors, Toronto-based life sciences company Cybin Inc. offered an update this morning on the status of its eight provisional patent applications. This latest news follows Cybin’s recent acquisition of Adelia Therapeutics, made with the express purpose of “advancing Cybin’s ability to innovate our psychedelic drug development program.”

The provisional patent applications include the development of oral film delivery mechanisms, among other delivery technologies, which Truffle Report has previously discussed in detail with Cybin’s chief medical officer Dr. Jukka Karjalainen. It appears these will be expanded from use with synthetic psilocybin into a medium for administering any further psychedelic compounds, existing or novel, that the company should produce in future.

Cybin CEO on Therapeutics Program

On that note, Cybin also announced its intention to expand its therapeutics program to encompass “psychedelic compounds such as DMT, psilocybin analogues and a range of tryptamines and phenethylamines which are expected to have improved pharmacokinetic profiles, while retaining the efficacy of the original molecules.”

Cybin CEO Doug Drysdale added that “Our management team has a proven track record in developing and commercializing dozens of therapeutics, including a modified psychedelic targeted for treatment resistant depression and we intend to continue to advance our IP portfolio, drug discovery platform, delivery mechanisms and technologies all with the end goal of enhancing the patient experience and progressing the psychedelic industry.”

Drug Delivery Systems, Novel Compounds, and Psychedelic Logistics

While the large scale rollout of legal, commercially available psychedelic therapy is still a highly speculative discussion, with significant strides having been made in recent months. TheraPsil, a Canadian non-profit devoted to psilocybin-assisted therapy for cancer patients, has made substantial progress by obtaining Section 56 exemptions via Health Canada from the Controlled Drugs and Substances Act in order to treat patients and train therapists. Just this morning, Alberta-based ATMA Journey Centres Inc. announced that it had conducted the first legally exempted psychedelic-assisted therapy for a palliative patient by a private company. These tentative steps are exciting, but there is still a long road ahead.

As we’ve previously discussed with multiple leaders in the public and private sectors, the future of psychedelic therapy will be largely determined by accessibility, the logistics and costs of treatment, and availability of safe and effective drug delivery mechanisms. The company or companies that can successfully lead the space, maintaining diversity and flexibility across the widest range of mental health indications and psychedelic compounds, stand to reap the greatest rewards.

See Also
lobe sciences company profile

Truffle Report wishes to disclose that Cybin Inc. is a client of our parent company, Puff Digital. The content of this article was not solicited or sponsored in any way.

Further, the author of this piece wishes to disclose that he owns shares of Cybin Inc.

Can you experience #psilocybin withdrawal?

Chemical dependence isn't usually an issue with psychedelics, but it's important to examine your relationship with any substance, particularly one that is fast becoming a mental health fix.

Full article here:

"Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe."

Beckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines.

Introduced by Representative @PeterforMO, a new bill in Missouri proposes to significantly decrease penalties for possession of #psychedelics, #cannabis, and other controlled substances.

Full story here:

#missouri #missourinews #legal #statelaw

Covering psychedelics reform in 2022—and its rapidly growing bipartisan appeal—has been so interesting. Like:

“We don't need to lock up people because they ate some mushrooms” is something a GOP lawmaker in one of the most conservative state legislatures casually just told me.

Load More...

Related Articles

Scroll To Top